Theravance Drug Fails Another Pivotal Test, Sparking Restructuring, Possible Sale

Дата публикации: 04-03-2026 19:00:00

Ampreloxetine’s Phase 3 failure in multiple system atrophy is the third disappointing clinical trial outcome for the Theravance Biopharma drug.

Схожие новости

#	Наименование новости	Тональность	Информативность	Дата публикации
1	STAT+: Novo Nordisk inflammation-targeting drug misses mark in heart disease study	0	7.41	31-07-2026
2	STAT+: Pharmalittle: We’re reading about a Novo setback, support for Replimune’s melanoma drug, and more	0	8.36	31-07-2026
3	STAT+: Pharmalittle: We’re reading about an FDA panel nixing a Duchenne drug, FTC suing Hims & Hers, and more	0	7.23	30-07-2026
4	The FDA Issues a Xanax Recall After the Drug Failed To Meet Certain Specifications	0	5.8	16-04-2026
5	Capricor’s data clash and a fugitive in the C-suite	0	12.07	30-07-2026
6	Sleep Apnea Sufferers May Soon Be Able To Reach for a Pill To Deal With Their Condition	0	8.46	13-03-2026
7	Thyroid medicine recalled nationwide: FDA	0	7.09	28-07-2026
8	Thyroid medicine recalled nationwide: FDA	0	7.09	28-07-2026
9	Abivax прекратила испытания своего препарата от COVID-19	0	0	05-03-2021

Классификация: Пресс-релизы. Схожих патентов: 0. Схожих новостей: 9. Тональность: 0. Информативность: 11.1. Источник: dealbreaker.com.